Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Daniel R. Passeri acquired 30,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were bought at an average price of $1.03 per share, for a total transaction of $30,900.00. Following the acquisition, the chief executive officer now owns 164,578 shares in the company, valued at approximately $169,515.34. This trade represents a 22.29 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Cue Biopharma Stock Up 0.9 %

Cue Biopharma stock traded up $0.01 during mid-day trading on Wednesday, hitting $1.07. The company’s stock had a trading volume of 414,263 shares, compared to its average volume of 453,138. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. Cue Biopharma, Inc. has a 52-week low of $0.45 and a 52-week high of $3.20. The firm’s 50 day moving average is $1.32 and its 200 day moving average is $1.05. The company has a market cap of $67.78 million, a PE ratio of -1.19 and a beta of 1.66.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus cut their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.00.

Institutional Trading of Cue Biopharma

A number of hedge funds have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new position in Cue Biopharma during the second quarter valued at approximately $66,000. GSA Capital Partners LLP increased its stake in shares of Cue Biopharma by 5.1% during the 3rd quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock worth $221,000 after purchasing an additional 14,104 shares during the last quarter. Good Life Advisors LLC raised its holdings in shares of Cue Biopharma by 23.1% during the 3rd quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock valued at $303,000 after purchasing an additional 75,000 shares in the last quarter. Sigma Planning Corp lifted its stake in shares of Cue Biopharma by 50.9% in the 3rd quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock valued at $304,000 after purchasing an additional 135,295 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Cue Biopharma by 3.3% in the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after purchasing an additional 16,371 shares in the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.